Arcellx, Inc.

Arcellx, Inc.

ACLXNYSE / NASDAQHealthcareSmall cap

$115.07$0.00 (0.0%)

Last close · Data as of Apr 29, 2026

Market cap
$6.7B
P/E
-29.4x
EV / EBITDA
-30.2x
Revenue
$22.3M
Net margin
-1027.3%
ROCE
-50.6%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Arcellx, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 29 Apr 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $115 to $115 · Last close Apr 29, 2026

Best weekday to invest, historically

The same weekly amount in ACLX, bought on each weekday since 2022.

News & filings

What Arcellx filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 229 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 4.44 times current liabilities.
  • Prices are as of 29 Apr 2026; price-based points are paused until newer prices arrive.

Prices to the 29 Apr 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Read moreShow less

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Sector
Healthcare
Shares outstanding
57.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.7B
P/E
-29.4x
P/B
16.7x
EV / EBITDA
-30.2x
EV / Sales
300.8x
P/S
302.1x
52-week high
$115.10
52-week low
$52.80

Profitability

Operating margin
-1135.6%
Net margin
-1027.3%
EBITDA margin
-997.0%
ROE
-56.9%
ROCE
-50.6%
ROIC
-48.3%
ROA
-37.9%
Asset turnover
0.04

Growth

Revenue
$22.3M
Revenue growth, 1Y
-79.4%
Net profit growth, 1Y
113.3%
Free cash flow
-$212.6M

Solvency

Current ratio
4.44
Debt / Equity
0.13
Debt / Assets
0.09
CFO / Net profit
0.92
Cash / Market cap
1.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$22.3M
Gross profit$22.3M
Operating expenses$275.4M
Research and development$157.6M
Selling, general and administrative$117.8M
Operating income-$253.1M
Interest and other$24.2M
Pretax income-$228.9M
Tax and other$70.0k
Net income-$228.9M

Revenue and net profit

Revenue fell 79.4% in FY2025; net profit is the dashed line.

Arcellx, Inc. revenue and net profit by fiscal year
Arcellx, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$188.7M
FY2023$110.3M-$70.7M
FY2024$107.9M-$107.3M
FY2025$22.3M-$228.9M

Cash flows

FY2025: -$210.3M from operations, -$212.6M free after investment (dashed).

Arcellx, Inc. operating and free cash flow by fiscal year
Arcellx, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$99.3M-$101.6M
FY2023$207.6M$186.1M
FY2024-$83.5M-$96.9M
FY2025-$210.3M-$212.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$22.3M-79.4%1Y
EBITDA
-$222.2M
Net profit
-$228.9M
Cash from operations
-$210.3M
Free cash flow
-$212.6M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$22.3M-$222.2M-$228.9M-$212.6M-56.9%-79.4%+113.3%

Monthly returns

Month-by-month returns of ACLX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$604.0M
Liabilities$201.6M
Equity$402.4M
Paid-in capital$1.1B
Retained earnings-$725.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ACLX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Arcellx, Inc. (this company)300.8x

Not shown (no positive earnings and no EV / Sales): Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Arcellx, Inc.ACLXthis company$6.7B-29.4x16.7x-56.9%-30.2x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Immunovant, Inc.IMVT$6.7B-13.3x7.9x-59.3%-10.9x
Lantheus Holdings, Inc.LNTH$6.7B28.7x6.1x21.4%17.2x
Hims & Hers Health, Inc.HIMS$6.5B50.5x12.0x23.7%46.1x
Peer median—-9.2x7.4x-25.0%4.2x

Year-to-date ROI

ACLX since 1 January, against earlier years.

Historical volatility

ACLX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Arcellx, Inc. operating margin by fiscal year
Arcellx, Inc. operating margin by fiscal year
DateOperating margin
FY2023-81.5%
FY2024-127.5%
FY2025-1135.4%
LineFY2025
Operating expensesOperating Expense$275.4M
Research and developmentResearch And Development$157.6M
Total expensesTotal Expenses$275.4M
Pretax incomePretax Income-$228.9M

Learn while you research

Academy chapters picked for Arcellx, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →